Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Network meta-analysis models to account for variability in treatment definitions: application to dose effects.
Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis.
MRI-based clinical trials in relapsing-remitting MS: new sample size calculations based on a longitudinal model.
Optical Coherence Tomography Detection of Neurodegeneration in Multiple Sclerosis.
The Management of Pediatric Multiple Sclerosis.
Interleukin-2 and the brain: dissecting central versus peripheral contributions using unique mouse models.
Do cortical lesions help us to distinguish MS from NMO?
Aggregation of MBP in chronic demyelination.
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis (OLTERMS)
Biomarkers of treatment response in multiple sclerosis.
Balance and Gait in People with Multiple Sclerosis: A Comparison with Healthy Controls and the Immediate Change after an Intervention based on the Bobath Concept.
Framework for Assessment of the Usability of Lower-Extremity Robotic Exoskeletal Orthoses.
Longitudinal study of alexithymia and multiple sclerosis.
Cutting Edge: IL-6-Dependent Autoimmune Disease: Dendritic Cells as a Sufficient, but Transient, Source.
Neuroinflammatory Imaging Biomarkers: Relevance to Multiple Sclerosis and its Therapy.
Long-term MRI findings in neuromyelitis optica: seropositive versus seronegative patients.
Neuroendocrine Immunoregulation in Multiple Sclerosis.
Markers of oxidative stress in plasma and saliva in patients with multiple sclerosis.
Validation survey of the impact of urinary incontinence (IIQ-7) and inventory of distress urogenital (UDI-6) - the short scales - in patients with multiple sclerosis.
FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS.
Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab.
Fatigue and health-related quality of life in relapsing-remitting multiple sclerosis after 2 years glatiramer acetate treatment are predicted by changes at 6 months: an observational multi-center study.
Simvastatin affects cell motility and actin cytoskeleton distribution of microglia.
Advanced diffusion MRI fiber tracking in neurosurgical and neurodegenerative disorders and neuroanatomical studies: A review.
Neuroprotective agent riluzole potentiates postsynaptic GABA(A) receptor function.

Pages